IO Biotech Shares Surge on Renewed Regulatory Prospects
Published on 11/19/2025 at 15:47 | Redaktion boerse-global.de
IO Biotech witnessed a dramatic single-day surge of more than 25% in its share price yesterday. This powerful rally was fueled by the company’s latest quarterly financial report and significant progress in the regulatory pathway for its cancer vaccine candidate, Cylembio.
A pivotal development driving investor sentiment is the scheduled meeting with the U.S. Food and Drug Administration (FDA) in December 2025. This meeting is set to finalize the design for a new Phase 3 clinical trial for Cylembio. The event represents a critical step forward, coming just months after the FDA had previously advised against a regulatory filing for the drug, a move that had triggered a significant stock decline and Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
